Company intelligence / Profile preview
AxImmune
Fort Collins, Colorado, United Statesaximmune.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AxImmune is developing Ax-101, a small molecule immuno-oncology drug shown in preclinical and limited human studies to have potent anti-tumor activity, both as monotherapy and synergistically with immune checkpoint inhibitors. No significant drug-related adverse effects were observed in early trials. The company aims to expand patient response to checkpoint therapies.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Colorado State UniversityAxon Connected, LLC
Beyond the preview
Go deeper on AxImmune.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AxImmune.